

Form PTO-1449 (Modified)

DEC 12 2000

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28758/36072Serial No.
09/495 448

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
Lester F. LauFiling Date
January 31, 2000Group
1643

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
W	A1	5,408,040	04/18/95	Grotendorst, G.R. <i>et al.</i>	530	399	
W	A2	4,554,101	11/19/85	Hopp, T. P.	260	112.5	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
W	B1	EP 0 495 674	07/22/92	EPO				
W	B2	WO 96/01896	01/25/96	WIPO				


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

W	C1	Adra, C.N. <i>et al.</i> , "Cloning and expression of the mouse <i>pgk-1</i> gene and the nucleotide sequence of its promoter," <i>Gene</i> , 60:65-74 (1987).					
	C2	Ahrens, P.B. <i>et al.</i> , "Stage-Related Capacity for Limb Chondrogenesis in Cell Culture," <i>Developmental Biology</i> , 60:69-82 (1977).					
	C3	Bradham, D.M. <i>et al.</i> , "Connective Tissue Growth Factor: a Cysteine-rich Mitogen Secreted by Human Vascular Endothelial Cells Is Related to the SRC-induced Immediate Early Gene Product CEF-10," <i>Journal Cellular Biology</i> , 114(6):1285-1294 (September, 1991).					
	C4	Fajardo, L.F. <i>et al.</i> , "Methods in Laboratory Investigation: The Disc Angiogenesis System," <i>Laboratory Investigation</i> , 58(6):718-724 (1988).					

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28758/36072	Serial No. 09/495,448
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Lester F. Lau		
		Filing Date January 31, 2000	Group 1643	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
C15	<i>CW</i>	Ryseck, R-P. <i>et al.</i> , "Structure, Mapping, and Expression of <i>fisp</i> -12, a Growth Factor-inducible Gene Encoding a Secreted Cysteine-rich Protein," <i>Cell Growth and Differentiation</i> , 2:225-233 (May, 1991).
C16		Spooncer, E. <i>et al.</i> , "Continuous <i>in vitro</i> generation of multipotential stem cell clones from src-infected cultures," <i>Nature</i> , 310:288-230 (July, 1984).
C17		Tolsma, S.S. <i>et al.</i> , "Peptides Derived from Two Separate Domains of the Matrix Protein Thrombospondin-1 Have Anti-Angiogenic Activity," <i>Journal of Cell Biology</i> , 122(2):497-511 (July, 1993).
C18		Yang, G.P. <i>et al.</i> , "Cyr61, Product of a Growth Factor-inducible Immediate Early Gene, Is Associated with the Extracellular Matrix and the Cell Surface," <i>Cell Growth and Differentiation</i> , 2:351-357 (July, 1991).
C19		Yang, G.P., "BIOCHEMICAL AND FUNCTIONAL ANALYSIS OF CYR61, THE PRODUCT OF A GROWTH FACTOR-INDUCIBLE IMMEDIATE EARLY GENE." Ph.D. THESIS, University of Illinois at Chicago, Chicago, Illinois (1993).

Duplicate CW

RECEIVED

DEC 18 2000

TECH CENTER 1600/2900

EXAMINER <i>Gautier</i>	DATE CONSIDERED <i>3/21/03</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]


Examiner Signature		Date Considered	3/21/03
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

50069518



Creation date: 02-23-2004
Indexing Officer: DTURNER2 - ANJANETTE TURNER
Team: OIPEBackFileIndexing
Dossier: 09495448

Legal Date: 05-27-2003

No.	Doccode	Number of pages
1	LET.	2
2	A...	1
3	SPEC	1
4	CLM	1
5	REM	6
6	CRFL	2
7	SEQLIST	22

Total number of pages: 35

Remarks:

Order of re-scan issued on